RNS Number:3918B
Lombard Medical Technologies PLC
12 April 2006



  Lombard Medical Presents Positive 12 month Clinical Data for AorfixTM Stent
                     Graft at Major International Symposium


London, UK, 12 April 2006 - Lombard Medical Technologies PLC ("Lombard Medical")
announces positive clinical results on its AorfixTM stent graft, presented
yesterday at the 28th Charing Cross International Symposium at Imperial College,
London.  Twelve month follow-up data on 24 trial patients was reported,
demonstrating freedom from all endoleaks, fracture, migration or kinking.  In
addition, AorfixTM offers hope to those patients with tortuous anatomy of the
abdominal aorta, who were once thought as untreatable by conventional aortic
stent grafts.  First clinical implants of the improved device and delivery
system promise quicker and easier deployment of the stent graft, making it a
more comfortable procedure for clinician and patient.


AorfixTM has been used in more than 130 patients worldwide.  Several abdominal
aortic aneurysm (AAA) bifurcated stent grafts have exceeded 24 months of
implantation with no device related adverse clinical outcomes.


Lombard Medical also reports that NICE (National Institute for Health and
Clinical Excellence) has recently issued a new Interventional Procedure
Guidance. This confirms that current evidence on the efficacy and short-term
safety of stent graft placement in AAA appears adequate to support the use of
this procedure provided that the normal arrangements are in place for consent,
audit and clinical governance.


NICE recommends in particular that patients should understand the risks of
endovascular leaks, the possibility of secondary intervention and the need for
lifelong follow-up. The most common adverse event reported in a meta-analysis of
three randomised controlled trials following stent graft placement was device
related endoleaks, which occurred in 19% of patients within the first year.
Technical complications included stent migration, which happened in 1% of
patients, and stent wire fracture, which happened in 3% of patients, both within
the first year.  Recent developments, however, such as Lombard Medical's Aorfix
TM device, have led to lower incidence of procedural and post-procedural
complications.


Alistair Taylor, Executive Chairman of Lombard Medical, said:


"We have presented highly positive clinical data on our AorfixTM stent graft,
showing excellent results at 12 months, particularly in terms of no endoleaks,
strong migration resistance and significant aneurysm shrinkage.


"AorfixTM will make a real contribution to the development of stent graft
placement in AAA by offering less risk and trauma to a wider range of patients
than ever before, more clinical choices to medical practitioners and improved
cost effectiveness of this procedure."




Enquiries:


Lombard Medical Technologies PLC
Tel: 01235 750 800
Alistair Taylor, Executive Chairman
Brian Howlett, Chief Executive Officer


Financial Dynamics
Tel: 020 7831 3113
David Yates / John Gilbert




Notes to editors

Lombard Medical is a medical devices company developing stent grafts and other
medical products for use in the treatment of vascular disease.  The Company's
lead product, AorfixTM, is a stent graft for the treatment of aortic aneurysms,
a balloon-like enlargement of the aorta which, if untreated, may rupture and
cause death.  Abdominal and thoracic aortic aneurysms are the 13th largest cause
of death in the US and the market is estimated to be worth approximately US$2
billion by 2010.  AorfixTM is currently being commercialised in the EU, with US
clinical trials expected to commence during 2006.  The Company has a strategic
collaboration with one of the world's leading medical devices companies, Boston
Scientific.


Lombard Medical has recently successfully completed its initial public offering
on AIM and was admitted to listing in December 2005, raising #23.9 million, net
of expenses.  The Company, based in Oxfordshire & Yorkshire, currently employs
47 people.


Further background on the Company can be found at www.lombardmedical.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

RESQFLFFQZBZBBB
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Lombard Medical Technologies Charts.
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Lombard Medical Technologies Charts.